Your session is about to expire
← Back to Search
Tyrosine kinase 2 (TYK2) blocker
Deucravacitinib for Psoriasis
Phase 4
Waitlist Available
Led By Raymond Cho, MD, PhD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
18 years of age or older
Patients with moderate-severe psoriasis (BSA >= 10%, PASI >=12, static Physician's Global Assessment (sPGA) 3 and above)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-treatment, 4 months
Awards & highlights
Study Summary
This trial looks at how psoriasis patients' skin & blood cell health is affected by a new drug.
Who is the study for?
Adults with moderate to severe psoriasis (covering at least 10% of their body, with a severity score of 12 or more) can join this trial. They shouldn't have tuberculosis, serious infections, be pregnant or breastfeeding, have used immunosuppressives recently, suffer from severe immune system problems, or any condition that might risk safety or data quality.Check my eligibility
What is being tested?
The trial is testing deucravacitinib's effect on skin and blood immune cells in psoriasis patients. It involves taking the TYK2 inhibitor deucravacitinib and monitoring how it changes the function of these cells before and after treatment starts.See study design
What are the potential side effects?
Deucravacitinib may cause side effects such as increased risk of infections due to its action on the immune system. Specific side effects are not listed but generally relate to its role in altering immune cell functions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
My psoriasis is severe, covering more than 10% of my body.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ pre-treatment, 4 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-treatment, 4 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Psoriasis Area and Severity Index (PASI) score
Side effects data
From 2022 Phase 3 trial • 220 Patients • NCT0416746218%
Upper respiratory tract infection
8%
Mouth ulceration
7%
Nasopharyngitis
5%
Pruritus
5%
Headache
3%
Folliculitis
3%
Psoriasis
1%
Cholecystitis
1%
Gastroenteritis shigella
1%
Gastroenteritis
1%
Pharyngitis
1%
Diabetes mellitus
1%
Accidental overdose
1%
Hepatobiliary procedural complication
1%
Psoriatic arthropathy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo Week 0 up to Week 16
BMS-986165 Week 0 up to Week 52
BMS-986165 Week 16 up to Week 52
Trial Design
1Treatment groups
Experimental Treatment
Group I: deucravacitinib treatmentExperimental Treatment1 Intervention
treatment with deucravacitinib for 6 months
Find a Location
Who is running the clinical trial?
University of California, San FranciscoLead Sponsor
2,501 Previous Clinical Trials
15,236,546 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,638 Previous Clinical Trials
4,128,489 Total Patients Enrolled
Raymond Cho, MD, PhDPrincipal InvestigatorUniversity of California, San Francisco
4 Previous Clinical Trials
75 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have an active cancer that is affecting my whole body.I am 18 years old or older.I do not have tuberculosis or any serious infection.My psoriasis is severe, covering more than 10% of my body.I have not taken any immunosuppressive drugs in the last 12 weeks.I have a severe immune system problem.
Research Study Groups:
This trial has the following groups:- Group 1: deucravacitinib treatment
Awards:
This trial has 3 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is deucravacitinib a viable and secure course of treatment for patients?
"The data on hand indicates the safety of deucravacitinib to be a 3, due to this being a Phase 4 trial and thus having regulatory clearance."
Answered by AI
Are individuals younger than four decades of age invited to participate in this research?
"According to the protocol, individuals aged 18-75 are eligible for this clinical trial. Notably, there are 29 research initiatives targeting juveniles and 132 that cater exclusively to seniors."
Answered by AI
What are the eligibility criteria for enrolling in this trial?
"In order to qualify for this medical research, candidates must have plaque psoriasis and be aged 18-75. This trial has limited slots available, with 25 people able to join in total."
Answered by AI
Is enrollment still open for this scientific inquiry?
"A review of the clinicaltrials.gov webpage reveals that this research initiative is no longer seeking candidates; although, it was initially posted on July 1st 2023 and last updated in May 4th 2023. But don't fret! There are 159 other trials currently accepting participants at present."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger